Company intelligence / Profile preview

Y2 Solution

Hwaseong, Gyeonggi-do, South Koreay2solution.com ↗

Ownership: Private
Development stage: Other

Overview

Y2 Solution, through its joint venture Luxa Biotechnology with the Neural Stem Cell Institute, is developing a retinal pigment epithelium stem cell implant for dry age-related macular degeneration. The company has initiated clinical trials in the United States and recently received a $4 million grant to support further study of its RPESC-RPE 4W transplantation approach. No published efficacy or safety results yet.

Therapeutic areas: Ophthalmology
Modalities: Cell therapy
Industry: Biotech

Partnerships

Neural Stem Cell Institute (NSCI)California Institute for Regenerative Medicine

Beyond the preview

Go deeper on Y2 Solution.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y2 Solution.

Explore the full profile